Self-adjuvant multiepitope nanovaccine based on ferritin induced long-lasting and effective mucosal immunity against H3N2 and H1N1 viruses in mice

Nie, Jiaojiao; Zhou, Yongfei; Ding, Fan; Liu, Xiaoxi; Yao, Xin; Xu, Lipeng; Chang, Yaotian; Li, Zeyu; Wang, Qingyu; Zhan, Li; Zhu, Lvzhou; Xie, Kunpeng; Li, Chenxi; Shi, Yuhua; Zhao, Qi; Shan, Yaming

doi:10.1016/j.ijbiomac.2024.129259

Cited by 4 publications

(3 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(vii) PNPs smaller than 100 nm are readily taken up by peripheral or lymph node dendritic cells [ 32 ] for presentation of the antigen to trigger T cell immune responses [ 33 , 34 ]. (viii) Many PNP-based platforms display adjuvant properties [ 35 , 36 , 37 , 38 , 39 ], so vaccine delivery based on the PNP platform allows co-administration of the antigen, as well as the adjuvant simultaneously to the same immune cell for more robust immunological responses. (ix) Unlike the soluble antigens that can readily diffuse through the membranes of the blood endothelium and enter the blood circulation for faster systemic distribution, the particulate PNP-based vaccines have limited systemic distribution as they are transported in lymph to reach the lymph nodes.…”

Section: Protein-based Nanoparticle (Pnp) Vaccine Platforms: Classifi...mentioning

confidence: 99%

Protein Nanoparticles as Vaccine Platforms for Human and Zoonotic Viruses

Pandey,

Sahoo,

Pattnaik

2024

Viruses

View full text Add to dashboard Cite

Vaccines are one of the most effective medical interventions, playing a pivotal role in treating infectious diseases. Although traditional vaccines comprise killed, inactivated, or live-attenuated pathogens that have resulted in protective immune responses, the negative consequences of their administration have been well appreciated. Modern vaccines have evolved to contain purified antigenic subunits, epitopes, or antigen-encoding mRNAs, rendering them relatively safe. However, reduced humoral and cellular responses pose major challenges to these subunit vaccines. Protein nanoparticle (PNP)-based vaccines have garnered substantial interest in recent years for their ability to present a repetitive array of antigens for improving immunogenicity and enhancing protective responses. Discovery and characterisation of naturally occurring PNPs from various living organisms such as bacteria, archaea, viruses, insects, and eukaryotes, as well as computationally designed structures and approaches to link antigens to the PNPs, have paved the way for unprecedented advances in the field of vaccine technology. In this review, we focus on some of the widely used naturally occurring and optimally designed PNPs for their suitability as promising vaccine platforms for displaying native-like antigens from human viral pathogens for protective immune responses. Such platforms hold great promise in combating emerging and re-emerging infectious viral diseases and enhancing vaccine efficacy and safety.

show abstract

Section: Protein-based Nanoparticle (Pnp) Vaccine Platforms: Classifi...mentioning

confidence: 99%

Protein Nanoparticles as Vaccine Platforms for Human and Zoonotic Viruses

Pandey,

Sahoo,

Pattnaik

2024

Viruses

View full text Add to dashboard Cite

show abstract

“…(vii) PNPs smaller than 100 nm are readily taken up by peripheral or lymph node dendritic cells [24] for presentation of the antigen to trigger T cell immune responses [25,26]. (viii) Many PNP-based platforms display adjuvant properties [27][28][29][30][31], so vaccine delivery based on PNP platform allows co-administration of the antigen as well as the adjuvant simultaneously to the same immune cell for more robust immunological responses. (ix) Unlike the soluble antigens that can readily diffuse through the membranes of the blood endothelium and enter the blood circulation for faster systemic distribution, the particulate PNP-based vaccines have limited systemic distribution as they are transported in lymph to reach the lymph nodes.…”

Section: Advantages Of Pnp-based Vaccine Platforms and Potential Limi...mentioning

confidence: 99%

Protein Nanoparticles as Viral Vaccine Platforms

Pandey,

Sahoo,

Pattnaik

2024

Preprint

View full text Add to dashboard Cite

Vaccines are one of the most effective medical interventions, playing a pivotal role in treating infectious diseases. Although traditional vaccines comprising of killed, inactivated, or live attenuated pathogens have resulted in protective immune responses, negative consequences of their administration have been well-appreciated. Modern vaccines have evolved to contain purified antigenic proteins, epitopes, or antigen-encoding mRNAs, rendering them relatively safe. However, reduced humoral and cellular responses pose major challenges to modern vaccine platforms. Protein nanoparticle (PNP)-based vaccines have garnered substantial interest in recent years for their ability to present repetitive array of antigens for improving immunogenicity and enhancing protective responses. Discovery and characterization of naturally occurring PNPs from various living organisms such as bacteria, archaea, viruses, insects, and eukaryotes, as well as computationally designed structures and approaches to link antigens to the PNPs have paved the way for unprecedented advances in the field of vaccine technology. In this review, we focus on some of the widely used naturally occurring and optimally designed PNPs for their suitability as promising vaccine platforms for displaying native-like antigens from viral pathogens for protective immune responses. Such platforms hold great promise in combating emerging and re-emerging infectious diseases and enhancing vaccine efficacy and safety.

show abstract

“… 8 Nasal mucosal vaccination, which simulates natural viral infection, has the potential to trigger the production of immunoglobulin A (IgA) and immunoglobulin G (IgG) antibodies in the respiratory tract and stimulate cellular immune responses, thereby aiding in the establishment of immune protection as the primary line of defense against viral invasion. 9 , 10 Additionally, mucosal vaccination enhances public compliance and streamlines large-scale vaccination campaigns. 11 Hence, developing mucosal immunity in the upper respiratory tract emerges as a promising approach for managing SARS-CoV-2.…”

Section: Introductionmentioning

confidence: 99%

Immunogenicity of intranasal vaccine based on SARS-CoV-2 spike protein during primary and booster immunizations in mice

Yang,

Xie,

et al. 2024

Human Vaccines & Immunotherapeutics

Self Cite

View full text Add to dashboard Cite

Self-adjuvant multiepitope nanovaccine based on ferritin induced long-lasting and effective mucosal immunity against H3N2 and H1N1 viruses in mice

Cited by 4 publications

References 54 publications

Protein Nanoparticles as Vaccine Platforms for Human and Zoonotic Viruses

Protein Nanoparticles as Vaccine Platforms for Human and Zoonotic Viruses

Protein Nanoparticles as Viral Vaccine Platforms

Immunogenicity of intranasal vaccine based on SARS-CoV-2 spike protein during primary and booster immunizations in mice

Contact Info

Product

Resources

About